Xicheng W. Wang
19 Nonglinxia Road
Guangzhou, 510062, China
Guangzhou, 510062, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 52 publications
First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial.
Journal: JAMA oncology
Published: June 04, 2026
Comparative evaluation of isolation protocols for Aloe vera-derived extracellular vesicles.
Journal: Frontiers in pharmacology
Published: April 20, 2026
Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial.
Journal: Nature medicine
Published: January 29, 2026
Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: August 22, 2025
Bioequivalence of two doxorubicin liposome formulations (LY01612 and Caelyx) using free and encapsulated doxorubicin concentrations in Chinese patients with advanced breast cancer.
Journal: International journal of clinical pharmacology and therapeutics
Published: June 02, 2025
Taletrectinib in ROS1+ Non-Small Cell Lung Cancer: TRUST.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 03, 2025
The Mechanism of Ranunculus ternatus Thunb. against Esophageal Squamous Cell Carcinoma Based on Network Pharmacology and Experimental Verification.
Journal: Combinatorial chemistry & high throughput screening
Published: December 24, 2024
A plain language summary of results from the CHOICE-01 trial of toripalimab plus chemotherapy for advanced non-small cell lung cancer (NSCLC).
Journal: Future oncology (London, England)
Published: December 04, 2024
Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial.
Journal: Signal transduction and targeted therapy
Published: August 25, 2024
First-line serplulimab plus chemotherapy in extensive-stage small-cell lung cancer: Updated results and biomarker analysis from the ASTRUM-005 randomized clinical trial.
Journal: Cancer communications (London, England)
Published: August 06, 2024
Neutrophil serine proteases NE and PR3 controlled by the miR-223/STAT3 axis potentiate MASH and liver fibrosis.
Journal: Hepatology (Baltimore, Md.)
Published: July 08, 2024
Last Updated: 09/26/2026